Chronic Obstructive Pulmonary Disease (COPD):

Combination therapies to drive significant market growth

The prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, its impact on the wider health economy is significant and there remains considerable unmet clinical need. Valued at US$10 billion and with a 5 year CAGR of 7.1% this high growth sector is set for radical change as new products and combinations are introduced changing both the treatment and competitive landscapes.

The cosy carve up of the market between Pfizer’s Spiriva (tiotropium) and GSK’s Advair/Seretide (fluticasone propionate/salmeterol), which currently account for 75% of sales globally, will be challenged by new entrants that provide better patient adherence, improve lung function, tackle inflammation and reduce exacerbations of the disease.

Why is COPD causing such excitement?

There is considerable industry and investor excitement about COPD treatment developments.  Which of the new products will find favour with clinicians?  What regulatory hurdles must they overcome? Do they offer a real clinical improvement over current therapies?  Stripping away the hype and harnessing the real world insights from leading US and European KOL’s, this Therapy Trends analysis critically examines the products and research and exposes the real potential. For example:

  • In September 2013, Novartis’ Ultibro (glycopyrronium/indacaterol) was the first once daily fixed-dose LABA/LAMA to be approved, with promising research results and positive KOL opinion.  However, approved dosages of the indacterol element may be lower in the US, which could affect efficacy and take up.  Regulatory delay with the FDA is likely to hand the advantage to GSK, Boehringer Ingelheim and Almirall/Forest all of whom are likely to bring LABA/LAMA combinations to the US market before Novartis.
  • In May 2013, GlaxoSmithKline’s Breo/Relvar (fluticasone furoate/vilanterol), the first once-daily ICS/LABA was approved, but there are questions over whether it offers clinical value compared with Symbicort and Advair/Serodtide.  However, the tide could turn if the product could become the first COPD therapy to gain a mortality claim if the outcome of the SUMMIT trial is positive.  In the words of one KOL: “Let's assume that this study is positive. Then the whole field would change dramatically. This would cause an avalanche.”
  • Takeda’s Daxas/Daliresp (roflumilast) was the first, and remains the only, oral PDE-IV inhibitor available but sales are hampered by poor tolerability, unpleasant side effects, variable US formulary coverage and restrictions on use in some EU markets.  Chiesi’s CHF 6001 (Phase II) inhaled PDE-IV inhibitor is showing promising and is “extremely well tolerated in extended safety studies.”
A Complete Ongoing Analysis of Current Trends, Future Forecasts and Landscape Modifiers

For instant access to an accurate, unbiased, qualitative review of the latest treatment trends along with a five-year quantitative COPD market forecast look no further than FirstWord’s Therapy Trends: COPD. This comprehensive FirstWord research is available in two comprehensive modules:

  • The KOL Insight: COPD module provides a complete review and is enhanced with exclusive in-depth interviews with leading KOLs from the US and Europe
  • The Consensus Outlook: COPD data analysis module provides annual historical and forecast product-level sales data from an average of leading equity analysts’ projections. Key findings are provided in report which brings together data in charts and tables.
KOL Insight

KOL Insight Report

  • A qualitative analysis of the current and predicted treatment trends, clinical products and commercial changes in the global COPD market informed by in-depth expert views of leading clinicians
  • Compare the market’s key players, products, late-stage pipeline drugs, product positioning, in the context of COPD market trends.

Event Bulletins

  • Benefit from the latest KOL views about significant event driven changes in COPD treatment trends.
Consensus Outlook

Consensus Report

  • An in-depth 5-year Consensus Outlook report of predicted quantitative changes in key COPD market forecast parameters drawn from 13 leading analyst and brokerage companies
  • Chart COPD market size, product sales, market share by company, competitive status and detailed market forecasts

Interactive Analytics File

  • Use the interactive Excel market analytics module of detailed market and product sales data from 2007 to 2017 to drill down and assess key company, market and product trends

Therapy Trends KOL Insight: COPD analyses the current and predicted key issues, current products and late-stage pipeline products. The report gives you qualitative, inside information from exclusive FirstWord interviews with 12 key opinion leaders (KOLs) through the following:

  • KOL Insight Report — an in-depth analytical report on COPD treatment trends
  • Full report updates — issued to you after each  and every significant COPD  market event
  • Event Bulletins — the latest KOL views in response to each event
Key Report Features and Benefits
  • Critical insights on products and market developments from leading US and European clinicians
  • Complete coverage of all therapeutic approaches
  • Assessment of current leading COPD products by sub sector
  • Analysis of late-stage pipeline COPD therapies by sub sector
  • Competitive evaluation of leading players
  • Current thinking and trends in the treatment of COPD and emerging approaches such as Muscarinic antagonist/beta2 agonists.
  • Predicted KOL treatment trends and market leaders
  • Ongoing clinical and market updates
All current therapeutic approaches covered
  • Long-acting muscarinic antagonists (LAMAs)
  • Long-acting beta2 agonists (LABAs)
  • Phosphodiesterase-IV (PDE-IV) inhibitors
  • Coverage of both their use as monotherapies or in combination
Expert Opinion for Real World Insights

The data and analysis in the report is enriched through the specific insights and opinions of leading clinicians working in COPD in the US and Europe. Their views on specific drugs and treatment pathways provide a unique front line perspective from those working in clinical setting. The results of these detailed and extensive interviews are incorporated though out the text so they can be read in the context of the issue or product being discussed.

Key Quotes from the Report
“I think what will be in the best interest of the COPD population is that the LABA/LAMA combination becomes accepted as foundation therapy for anyone with more than mild COPD. Patients who have moderate COPD would benefit most from being on a LABA/LAMA combination.”
Professor Christopher Cooper (US)
“I think we are looking at a major shift. The name of the game here is maximum bronchodilation. We need to provide the maximum bronchodilation as possible. We are working with two different mechanisms of action; so two mechanisms that complement each other so they are not excluding each other, so that they compliment. And that's the market; the way the market is looking and the way the market is shaping up. Everybody is like, 'well, this is probably the way for us to go.'”
Dr Antonio Anzueto (US)
“We desperately need new anti-inflammatory agents. That's what will take us to the next level. And this almost lemming rush that pharmaceutical companies have of doing the same thing as somebody else does so you can be the first to the market with it.”
Professor Byron Thomashow (US)
“The problem with Relvar/Breo is when you look at the data when they compared their new drug with their old drug there are no convincing differences. From my point of view it's a once-daily Advair. That's all it is.”
Professor Claus Vogelmeier (Europe)

Use this detailed report and powerful interactive Excel spread sheet to compare and contrast companies and products now and in the future. Therapy Trends Consensus Outlook: COPD includes the following comprehensive resources:

  • An in-depth forecast report based on consensus figures from 13 leading analysts. Rich in tables and charts, the report maps the impact of future events to predict product and company performance
  • An interactive forecast data analysis spreadsheet comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017
  • Timely event-driven market forecast report and data analysis updates over 12 months.
Report Features
  • Historical COPD sales from 2007—2012
  • Forecast COPD sales from 2013-2017
  • Key competitors and drug developers
  • Current and late-stage pipeline drugs
  • Future event mapping to forecast data points
  • Expected impacting factors on global forecasts
Use Consensus Outlook to
  • Chart predicted market growth and product sales
  • Map your own market parameters
  • Tailor your strategic and investment focus
  • Assess your current and future sales resources
  • Set proactive launches and branding strategies
Analysts Compared
  • Barclays Capital
  • Credit Suisse
  • Deutsche Bank
  • Goldman & Sachs
  • International Strategy & Investment
  • Jefferies
  • JP Morgan
  • Merrill Lynch
  • Morgan & Stanley
  • Societe Generale
  • Stifel Nicolaus
  • UBS
  • Wells Fargo
Content Highlights and Products Covered
  • FirstWord Analysis Highlights
  • Research Methodology
  • Chronic Obstructive Pulmonary Disease Marketplace
  • Key Chronic Obstructive Pulmonary Disease Developers
  • Chronic Obstructive Pulmonary Disease Class Dynamics
  • Spiriva (tiotropium; Boehringer Ingelheim/Pfizer) forecast
  • Eklira/Tudorza (aclidinium; Almirall/Forest) forecast
  • Seebri (glycopyrronium; Novartis) forecast
  • Ultibro (glycopyrronium/indacaterol; Novartis) forecast
  • Seretide/Advair (fluticasone propionate/salmeterol; GlaxoSmithKline) forecast
  • Relvar/Breo (fluticasone furoate/vilanterol; GlaxoSmithKline) forecast
  • Symbicort (budesonide/formoterol; AstraZeneca) forecast
  • Arcapta/Onbrez (indacaterol; Novartis) forecast
  • Daliresp/Daxas (roflumilast; Takeda/Forest) forecast
  • Anoro (umeclidinium/vilanterol; GlaxoSmithKline) forecast
  • Aclidinium/formoterol (Almirall/Forest) forecast
Request Sample

At a glance listings of those who contributed and the rich and varied sources accessed to produce this major analysis of the COPD market and its prospects.

Key Opinion Leaders
Dr Stephen Rennard isLarson Professor in the Department of Internal Medicine and Professor (courtesy) in the Department of Pathology and Microbiology at the University of Nebraska Medical Center
Dr Antonio Anzueto is Professor of Medicine, Pulmonary/Critical Care Medicine at University of Texas Health Science Center, San Antonio
Dr Donald P. Tashkin is Emeritus Professor of Medicine, Division of Pulmonary and Critical Care Medicine at David Geffen School of Medicine at University of California Los Angeles
Dr Edward Eden is Associate Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Dr Byron Thomashow is a Clinical Professor of Medicine at Columbia University Medical Center and an Attending Physician at the New York-Presbyterian Hospital
Professor Christopher Cooper is a Professor of Medicine and Physiology at David Geffen School of Medicine, University of California, Los Angeles
Professor Peter Barnes is a Professor of Thoracic Medicine at the National Heart and Lung Institute, Head of Respiratory Medicine at Imperial College and Honorary Consultant Physician at Royal Brompton Hospital, London
Dr Marc Miravitlles is Chest Physician & Senior Researcher, Department of Pneumology, Hospital Clinic, Barcelona
Dr Rene Aalbers is Consultant Physician, Respiratory Medicine at Martini Hospital, Groningen, The Netherlands
Professor Claus Vogelmeier is a Professor of Medicine and Head of Pulmonary Division at Marburg University Hospital, Germany.
Professor Maurizio Luisetti is a Professor of Respiratory Medicine at the University of Pavia, Italy. Professor Pascal Chanez is a Professor of Medicine, Departement des Maladies Respiratoires, INSERM, Aix Marseille Universite, Marseille, France.
Analysts >
  • Barclays Capital
  • Credit Suisse
  • Deutsche Bank
  • Goldman & Sachs
  • International Strategy & Investment
  • Jefferies
  • JP Morgan
  • Merrill Lynch
  • Morgan & Stanley
  • Societe Generale
  • Stifel Nicolaus
  • UBS
  • Wells Fargo
Products & Companies Covered
  • Spiriva (tiotropium; Boehringer Ingelheim/Pfizer)
  • Eklira/Tudorza (aclidinium; Almirall/Forest)
  • Seebri (glycopyrronium; Novartis)
  • Ultibro (glycopyrronium/indacaterol; Novartis)
  • Seretide/Advair (fluticasone propionate/salmeterol; GlaxoSmithKline)
  • Relvar/Breo (fluticasone furoate/vilanterol; GlaxoSmithKline)
  • Symbicort (budesonide/formoterol; AstraZeneca)
  • Arcapta/Onbrez (indacaterol; Novartis)        
  • Daliresp/Daxas (roflumilast; Takeda/Forest)
  • Anoro (umeclidinium/vilanterol; GlaxoSmithKline)
  • Aclidinium/formoterol (Almirall/Forest)

Continually Updated in Response to Market Developments

The world of pharma is ever changing and executives must always be up-to-date with the latest developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends updated offers real commercial advantage. Consider the benefits:

  • Content will be fully updated in response to market developments such as new product approvals or pivotal research results for 12 months from the date of purchase
  • Such updates are incorporated throughout the KOL reports ensuring the change is reflected in every aspect of the report
  • There is no limit and all relevant events will result in an update
  • You’ll receive these updated directly, within days of each event’s occurrence
  • All updates are included in the price.

Whatever happens in the market you’ll always be able
to assess the impact with FirstWord Therapy Trends.

Unrivalled Sources Ensure Complete Coverage

Our unique disease selection matrix pinpoints those disease sectors of the highest commercial potential, and draws information from multiple novel and expert sources, including:

  • Exclusive views from leading global experts
  • Comprehensive consensus research
  • Live dispatches and critical industry data
  • Online opinions from 535,000 vetted physicians
  • Data from over 125 medical conferences each year
  • Over 2,000 peer-reviewed medical journals
  • Over 450 pharmaceutical news sources

KOL Insight and Consensus
Outlook Modules

Publication date:
 January 2014
 PDF + Excel
 149 + Data File

Select License

KOL Insight + Consensus Outlook:
$7,495 Single User License

Single user licenseAuthorizes use by the person placing the order only.

$14,990 Team License

Team licenseAuthorizes use by up to 10 employees of the Licensee who work within the same team or functional business unit.

$22,485 Global License

Global licenseAuthorizes use by any employee of the Licensee, including employees of the Licensee's affiliates.

Order Now

KOL Insight Benefits

  • Understand and assess future COPD market development
  • Analyse current and future treatment algorithm
  • Understand the market dynamics between the LAMA's, LABA's, combination ICS/LABA's and fixed dose LAMA/LABA's
  • Assess how prescribing trends will change with launch of new products
  • Learn about late-stage pipeline products
  • Track KOL views for the next 12 months

Consensus Outlook Benefits

  • Evaluate future sales forecasts and predicted market growth
  • Map your market parameters and chart commercial prospects
  • Assess market share by company and product
  • Tailor your strategic and investment focus based on the competition
  • Set proactive launch and branding strategies
  • Keep up with event-driven market data updates

Request Sample

Informing users in:

  • Business development
  • New product planning
  • Strategic brand planning
  • Market research
  • Competitive Intelligence
  • Forecasting and market analytics
  • Medical affairs
  • Clinical trials
  • Relationship management
  • Market Access
  • Marketing
  • Sales